Miriam Fernández

Miriam Fernández is a prominent investment strategist at Ibercaja Gestión, known for her expertise in thematic investing within the pharmaceutical sector. She has been vocal about the potential of emerging biopharmaceutical companies like Zealand Pharma to disrupt established players such as Novo Nordisk and Eli Lilly in the obesity treatment market.